浏览全部资源
扫码关注微信
疏肝益胆方治疗肝郁胆虚型原发性早泄的临床观察及作用机制分析
Clinical efficacy and mechanisms of
Shugan Yidan Formula in treating primary premature ejaculation with liver depression and gallbladder deficiency syndrome- 北京中医药 2025年44卷第7期 页码：847-851
- 作者机构：
1.首都医科大学附属北京中医医院男科，北京 100010
2.中国中医科学院西苑医院男科，北京 100091
- 作者简介：
韩强，男，42岁，硕士，副主任医师。研究方向：中医男科学。
王任远，E-mail：chinesewry@live.cn
- 基金信息：国家自然科学基金资助项目(81973848);第七批全国老中医药专家学术经验继承工作项目（许昕工作室）;首都医科大学附属北京中医医院扶持学科基金项目
DOI：10.16025/j.1674-1307.2025.07.007
中图分类号：收稿日期：2024-05-27，
纸质出版日期：2025-07-25
- 稿件说明：
移动端阅览
韩强，曾银，王福，等.疏肝益胆方治疗肝郁胆虚型原发性早泄的临床观察及作用机制分析［J］.北京中医药，2025，44（7）：847-851.
HAN Qiang,ZENG Ying,WANG Fu,et al.Clinical efficacy and mechanisms of Shugan Yidan Formula in treating primary premature ejaculation with liver depression and gallbladder deficiency syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(07):847-851.
韩强，曾银，王福，等.疏肝益胆方治疗肝郁胆虚型原发性早泄的临床观察及作用机制分析［J］.北京中医药，2025，44（7）：847-851. DOI： 10.16025/j.1674-1307.2025.07.007.
HAN Qiang,ZENG Ying,WANG Fu,et al.Clinical efficacy and mechanisms of Shugan Yidan Formula in treating primary premature ejaculation with liver depression and gallbladder deficiency syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(07):847-851. DOI： 10.16025/j.1674-1307.2025.07.007.
摘要
目的
2
观察疏肝益胆方治疗肝郁胆虚型原发性早泄（PE）的临床疗效，同时观察外周血浆中5-HT、DA对PE治疗的影响。
方法
2
选取2022年10月—2023年10月于首都医科大学附属北京中医医院男科门诊就诊的原发性PE患者90例，采用随机数表法分为2组。观察组予疏肝益胆方治疗，对照组予盐酸达泊西汀片治疗，2组均治疗6周，随访2周。观察比较2组治疗前后射精潜伏期（IELT）、早泄诊断工具（PEDT）评分、早泄谱（PEP）评分、中医证候评分。分别于治疗前后检测患者外周血多巴胺（DA）及5-羟色胺（5-HT）水平。研究期间记录2组安全性指标情况。
结果
2
治疗后，2组PEDT、PEP、中医证候评分均较治疗前改善（
P
<
0.05），且观察组中医证候评分低于对照组（
P
<
0.05）。治疗后，2组IELT均较治疗前改善（
P
<
0.05），组间差异无统计学意义（
P
>
0.05）。治疗前后2组间血浆DA、5-HT水平比较，差异均无统计学意义（
P
>
0.05）；治疗后观察组血浆DA、5-HT水平较治疗前升高，但差异无统计学意义（
P
>
0.05）。治疗过程中，2组安全性指标均未见异常。
结论
2
疏肝益胆方临床有效性与达泊西汀无明显差异，但可改善患者情绪，且作用机制与外周血浆中的5-HT、DA水平无关。
Abstract
Objective
2
To observe the clinical efficacy of
Shugan Yidan Formula
in the treatment of primary premature ejaculation （PE） with liver depression and gallbladder deficiency syndrome， and to investigate the influence of peripheral plasma 5-hydroxytryptamine （5-HT） and dopamine （DA） on PE treatment.
Methods
2
Ninety patients with primary PE who visited the Andrology Department of Beijing Hospital of Traditional Chinese Medicine， Capital Medical University， from October 2022 to October 2023 were enrolled and randomly divided into two groups using a random number table. The observation group was treated with
Shugan Yidan Formula
， and the control group was treated with dapoxetine hydrochloride tablets. Both groups received treatment for six weeks and were followed up for two weeks. Intravaginal ejaculation latency time （IELT）， Premature Ejaculation Diagnostic Tool （PEDT） scores， premature ejaculation profile （PEP） scores， and traditional Chinese medicine （TCM） syndrome scores of th
e two groups were compared before and after treatment. Peripheral plasma levels of DA and 5-HT were measured before and after treatment. Safety indicators were recorded throughout the study.
Results
2
After treatment， PEDT， PEP， and TCM syndrome scores improved in both groups compared with baseline （
P
<
0.05）， with the TCM syndrome score in the observation group lower than that in the control group （
P
<
0.05）. IELT increased in both groups after treatment （
P
<
0.05）， with no significant difference between groups （
P
>
0.05）. There were no significant differences in plasma DA and 5-HT levels between the groups before or after treatment （
P
>
0.05）. Although DA and 5-HT levels in the observation group increased after treatment， the changes were not statistically significant （
P
>
0.05）. No abnormalities were observed in safety indicators in either group.
Conclusion
2
Shugan Yidan Formula
has comparable clinical efficacy to dapoxetine， can improve patients' emotional state， and its mechanism of action is not related to peripheral plasma levels of 5-HT or DA.
关键词
Keywords
references
SALONIA A , BETTOCCHI C , CARVALHO J , et al . EAU guidelines on sexual and eproductive health：limited update 2022 [EB/OL ] .[ 2024-03-19 ] . https://uroweb.org/guidelines/sexual-and-reproductive-healt https://uroweb.org/guidelines/sexual-and-reproductive-healt .
张敏建 , 张春影 , 金保方 , 等 . 早泄中西医结合诊疗指南(试行版) [J ] . 中华男科学杂志 , 2018 , 24 ( 2 ): 176 - 181 .
ALTHOF SE , MCMAHON CG , ROWLAND DL . Advances and missteps in diagnosing premature ejaculation: analysis and future directions [J ] . J Sex Med , 2022 , 19 ( 1 ): 64 - 73 .
EL-HAMD MA , SALEH R , MAJZOUB A . Premature ejaculation: an update on definition and pathophysiology [J ] . Asian J Androl , 2019 , 21 ( 5 ): 425 - 432 .
韩强 , 刘殿池 , 王和天 , 等 . 疏肝益气固涩法治疗早泄的临床观察 [J ] . 中国性科学 , 2017 , 26 ( 12 ): 80 - 82 .
MCMAHON CG , PORST H . Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent international society for sexual medicine criteria for lifelong premature ejaculation [J ] . J Sex Med , 2011 , 8 ( 10 ): 2707 - 2725 .
SEREFOGLU EC , MCMAHON CG , WALDINGER MD , et al . An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation [J ] . J Sex Med , 2014 , 11 : 1423 .
严世芸 , 朱邦贤 , 李德新 , 等 . GB/T 16751.2-2021 中医临床诊疗术语 第2部分：证候 [S ] . 北京 : 中国标准出版社 , 2021 : 223 .
MCMAHON CG . Dapoxetine for premature ejaculation [J ] . Expert Opin Pharmacother , 2010 , 11 （ 10 ）: 1741 - 1752 .
吴秀全 , 郭军 , 晏斌 , 等 . 基于“脑-心-肾-精室”轴浅析“石菖蒲-煅牡蛎-菟丝子”组药在治疗射精功能障碍疾病中的应用 [J ] . 北京中医药 , 2024 , 43 ( 3 ): 321 - 324 .
黄念文 , 毕焕洲 , 王彬 , 等 . 从肠道菌群角度探讨宁心安神法治疗早泄的作用机制 [J ] . 北京中医药大学学报 , 2023 , 46 ( 10 ): 1443 - 1448 .
MCMAHON CG . Dapoxetine for premature ejaculation [J ] . Expert Opin Pharmacother , 2010 , 11 ( 10 ): 1741 - 1752 .
高明 , 王磊 , 刘贺亮 , 等 . 男性不育症患者早泄的流行病学调查及早泄中医证型分布特点研究 [J ] . 中国性科学 , 2017 , 26 ( 8 ): 98 - 100 .
GUL M , BOCU K , SEREFOGLU EC . Current and emerging treatment options for premature ejaculation [J ] . Nat Rev Urol , 2022 , 19 ( 11 ): 659 - 680 .
BUVAT J , TESFAYE F , ROTHMAN M , et al . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries [J ] . Eur Urol , 2009 , 55 ( 4 ): 957 - 967 .
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备18046208号-2
京公网安备 11010102006710号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：272461 今日访问量：349